<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342355</url>
  </required_header>
  <id_info>
    <org_study_id>999904094</org_study_id>
    <secondary_id>04-I-N094</secondary_id>
    <nct_id>NCT00342355</nct_id>
  </id_info>
  <brief_title>Antiretroviral Therapy for Advanced HIV Disease in South Africa</brief_title>
  <official_title>Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine how well four different antiretroviral drug therapies work in
      patients with advanced HIV disease. The trial is part of the South Africa-U.S. Project
      Phidisa Programme - a collaboration between the South African Military Health Service (SAMHS)
      of the South African National Defense Force (SANDF), the U.S. Department of Defense, and the
      U.S. National Institutes of Health - to help prevent HIV transmission among South African
      military and civilian employees and their families.

      Members of the SANDF with HIV infection may be eligible for this study. HIV-infected family
      members who are 14 years of age and older may also participate. All participants must have a
      CD4 count of less than 200 or an AIDS-defining illness.

      Participants are randomly assigned to one of the following four antiretroviral drug regimens,
      which require taking 5 pills or more every day:

        -  AZT (zidovudine) + ddl (didanosine) + EFV (efavirenz)

        -  AZT (zidovudine) + ddl (didanosine) + r/LPV (lopinavir/ritonavir)

        -  D4T (stavudine) + 3TC (lamivudine) + EFV (efavirenz)

        -  D4T (stavudine) + 3TC (lamivudine) + r/LPV (lopinavir/ritonavir)

      Patients are followed for up to 6 years. Clinic visits are scheduled once a month for the
      first 3 months and then once every 3 months for the next five years. Patients undergo a
      medical history, physical examination, and blood tests at each visit, and complete
      questionnaires of behavior, quality of life, and force readiness every year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label 2x2 factorial study of four regimens of initial therapy.

      I. AZT + ddl + EFV

      II. AZT + ddl + r/LPV

      III. D4T + 3TC + EFV

      IV. D4T + 3TC + r/LPV

      Eligible patients will commence their randomly allocated study drugs as soon as possible
      after randomization. Episodes of treatment limiting toxicity will be managed in keeping with
      protocol specified guidelines.

      Patients who experience treatment failures (as specified in the protocol) will be managed by
      changing their regimen to that corresponding to one of the other treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.</measure>
    <time_frame>January 2004 until March 31 2008</time_frame>
    <description>Progression of disease, AIDS, or death in treatment naive patients with advanced HIV diagnosis will be evaluated in the four randomly assigned regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>January 2004 until March 31, 2008</time_frame>
    <description>Safety outcomes in four different randomly assigned regimens</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1771</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>AZT+DDI+EFV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine &lt;60 kg/125 mg twice daily or &gt;60kg/200 mg twice daily,Efavirenz 600 mg once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZT+DDI+r/LPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d4T+3TC+EFV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>d4T+3TC+r/LPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>600 mg once daily</description>
    <arm_group_label>AZT+DDI+EFV</arm_group_label>
    <arm_group_label>AZT+DDI+r/LPV</arm_group_label>
    <other_name>AZT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
    <description>40 mg once daily</description>
    <arm_group_label>d4T+3TC+EFV</arm_group_label>
    <arm_group_label>d4T+3TC+r/LPV</arm_group_label>
    <other_name>D4T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
    <description>&lt;60 kg/125 mg twice daily or &gt;60kg/200 mg twice daily</description>
    <arm_group_label>AZT+DDI+EFV</arm_group_label>
    <arm_group_label>AZT+DDI+r/LPV</arm_group_label>
    <other_name>DDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>300 mg once daily</description>
    <arm_group_label>d4T+3TC+EFV</arm_group_label>
    <arm_group_label>d4T+3TC+r/LPV</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600 mg once daily</description>
    <arm_group_label>AZT+DDI+EFV</arm_group_label>
    <arm_group_label>d4T+3TC+EFV</arm_group_label>
    <other_name>EFV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>r/LPV 400mg/100mg twice daily</description>
    <arm_group_label>AZT+DDI+r/LPV</arm_group_label>
    <arm_group_label>d4T+3TC+r/LPV</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Uniformed SANDF personnel or family members of SANDF personnel who are registered as
        eligible for health services from the SAMHS.

        HIV positive as diagnosed and/or confirmed in PHIDISA I OR documented HIV infection from an
        accredited source.

        CD4+ cell count less than 200 cells/microL (or less than or equal to 14% for patients
        post-splenectomy) AND/OR any AIDS defining illness currently or historically. Patients with
        pulmonary tuberculosis must have a CD4+ cell count less than 200 cells/microL. Patients
        with KS must have a CD4+ cell count less than 200 cells/microL unless their sarcoma is
        progressive and/or requires chemotherapy.

        Antiretroviral treatment naive (less than 7 days cumulative exposure to any antiretroviral
        drug) or treated for post-exposure prophylaxis without becoming HIV infected at that time.

        Laboratory variables as follows:

          1. Haemoglobin greater than or equal to 9.0g/dL for men and greater than or equal to
             8.0g/dL for women.

          2. Absolute neutrophil count greater than or equal to 500 cells/microL.

          3. Platelet count greater than or equal to 25,000/mm(3).

          4. Serum transaminase (ALT or AST) less than or equal to 5 times upper limit of normal
             (ULN).

             14 years or older.

             Likely to be compliant with study procedures and clinical visits in the opinion of the
             clinical investigator (guidance is provided in the protocol to assist clinicians in
             making this decision).

             Have completed the PHIDISA treatment adherence counseling session.

             Provision of written informed consent.

             EXCLUSION CRITERIA:

             Any history of pancreatitis or serious pathology indicative of increased risk for
             pancreatitis.

             Current requirement for use of a medication that is contra-indicated with the PHIDISA
             II study drugs. Where possible, alternate therapies should be selected in order to
             facilitate randomization. Patients entering the study with tuberculosis should defer
             screening and randomization until successful completion of an induction course of
             anti-mycobacterium therapy including rifampicin. As appropriate this patient could
             recommence screening when starting the maintenance regimen of anti-tubercular drugs
             excluding rifampicin.

             Pregnancy (following delivery, such women may be enrolled).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Polis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIH/NIAID</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Ratsela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAMHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South African Military Health Services (SAMHS)</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umtata Sickbay</name>
      <address>
        <city>Eastaern Cape</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3 Military Hospital</name>
      <address>
        <city>Free State</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1 Military Hospital</name>
      <address>
        <city>Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mtubatuba SIckbay</name>
      <address>
        <city>Kwazulu-Natal</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phalaborwa Sickbay</name>
      <address>
        <city>Limpopo</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Military Hospital</name>
      <address>
        <city>Western Cape</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugyenyi P, Munderi P, Darbyshire J. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet. 2002 Nov 9;360(9344):1503-5.</citation>
    <PMID>12433534</PMID>
  </reference>
  <reference>
    <citation>Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997 Sep 11;337(11):725-33.</citation>
    <PMID>9287227</PMID>
  </reference>
  <reference>
    <citation>Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998 Feb 21;351(9102):543-9.</citation>
    <PMID>9492772</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>September 14, 2009</results_first_submitted>
  <results_first_submitted_qc>March 4, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2013</results_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</investigator_affiliation>
    <investigator_full_name>Michael Polis, M.D.</investigator_full_name>
    <investigator_title>Michael Polis</investigator_title>
  </responsible_party>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>AIDS</keyword>
  <keyword>Opportunistic Infections</keyword>
  <keyword>Resource-Poor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZT+ddI+EFV</title>
          <description>Zidovudine + Didanosine+Efavirenz</description>
        </group>
        <group group_id="P2">
          <title>AZT + ddI + r/LPV</title>
          <description>Zidovudine + Didanosine + Lopinavir [LPV] co-formulated with ritonavir [RTV]</description>
        </group>
        <group group_id="P3">
          <title>d4T + 3TC + EFV</title>
          <description>Stavudine + Lamivudine + Efavirenz</description>
        </group>
        <group group_id="P4">
          <title>d4T + 3TC + r/LPV</title>
          <description>Stavudine + Lamivudine + lopinavir/ritonavir</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="444"/>
                <participants group_id="P4" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="444"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="444"/>
                <participants group_id="P4" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZT+ddI+EFV</title>
          <description>Zidovudine + Didanosine+Efavirenz</description>
        </group>
        <group group_id="B2">
          <title>AZT + ddI + r/LPV</title>
          <description>Zidovudine + Didanosine + Lopinavir [LPV] co-formulated with ritonavir [RTV]</description>
        </group>
        <group group_id="B3">
          <title>d4T + 3TC + EFV</title>
          <description>Stavudine + Lamivudine + efavirenz</description>
        </group>
        <group group_id="B4">
          <title>d4T + 3TC + r/LPV</title>
          <description>Stavudine + Lamivudine + lopinavir/ritonavir</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="444"/>
            <count group_id="B2" value="440"/>
            <count group_id="B3" value="444"/>
            <count group_id="B4" value="443"/>
            <count group_id="B5" value="1771"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="5.4"/>
                    <measurement group_id="B2" value="35.3" spread="5.4"/>
                    <measurement group_id="B3" value="35.5" spread="5.5"/>
                    <measurement group_id="B4" value="35.6" spread="5.5"/>
                    <measurement group_id="B5" value="35.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="142"/>
                    <measurement group_id="B5" value="567.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="300"/>
                    <measurement group_id="B4" value="301"/>
                    <measurement group_id="B5" value="1204.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="444"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="444"/>
                    <measurement group_id="B4" value="443"/>
                    <measurement group_id="B5" value="1771.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Safety outcomes in four different randomly assigned regimens</description>
        <time_frame>January 2004 until March 31, 2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZT+ddI+EFV</title>
            <description>Zidovudine + Didanosine+Efavirenz</description>
          </group>
          <group group_id="O2">
            <title>AZT + ddI + r/LPV</title>
            <description>Zidovudine + Didanosine + Lopinavir [LPV] co-formulated with ritonavir [RTV]</description>
          </group>
          <group group_id="O3">
            <title>d4T + 3TC + EFV</title>
            <description>Stavudine + Lamivudine + efavirenz</description>
          </group>
          <group group_id="O4">
            <title>d4T + 3TC + r/LPV</title>
            <description>Stavudine + Lamivudine + lopinavir/ritonavir</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Safety outcomes in four different randomly assigned regimens</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="444"/>
                <count group_id="O4" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.</title>
        <description>Progression of disease, AIDS, or death in treatment naive patients with advanced HIV diagnosis will be evaluated in the four randomly assigned regimens.</description>
        <time_frame>January 2004 until March 31 2008</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZT+ddI+EFV</title>
            <description>Zidovudine + Didanosine+Efavirenz</description>
          </group>
          <group group_id="O2">
            <title>AZT + ddI + r/LPV</title>
            <description>Zidovudine + Didanosine + Lopinavir [LPV] co-formulated with ritonavir [RTV]</description>
          </group>
          <group group_id="O3">
            <title>d4T + 3TC + EFV</title>
            <description>Stavudine + Lamivudine + efavirenz</description>
          </group>
          <group group_id="O4">
            <title>d4T + 3TC + r/LPV</title>
            <description>Stavudine + Lamivudine + lopinavir/ritonavir</description>
          </group>
        </group_list>
        <measure>
          <title>Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens.</title>
          <description>Progression of disease, AIDS, or death in treatment naive patients with advanced HIV diagnosis will be evaluated in the four randomly assigned regimens.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="444"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="444"/>
                <count group_id="O4" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24.7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZT+ddI+EFV</title>
          <description>Zidovudine + Didanosine+Efavirenz</description>
        </group>
        <group group_id="E2">
          <title>AZT + ddI + r/LPV</title>
          <description>Zidovudine + Didanosine + Lopinavir [LPV] co-formulated with ritonavir [RTV]</description>
        </group>
        <group group_id="E3">
          <title>d4T + 3TC + EFV</title>
          <description>Stavudine + Lamivudine + efavirenz</description>
        </group>
        <group group_id="E4">
          <title>d4T + 3TC + r/LPV</title>
          <description>Stavudine + Lamivudine + lopinavir/ritonavir</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="440"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="444"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="444"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="440"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="444"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="444"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="444"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="444"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="444"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobilary Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestattions</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="444"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="444"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury,poisoning, and procedure complications</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="444"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="440"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="444"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="440"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="444"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="444"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="444"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="444"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="440"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="444"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="440"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="444"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="444"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="444"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="444"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="443"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A Polis, MD, MPH</name_or_title>
      <organization>National Institute of Allergy and Infectious Diseases, Dvision of Clinical Research</organization>
      <phone>301-496-8027</phone>
      <email>mpolis@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

